[Immunotherapy in renal cell carcinoma: A booming clinical research]. – UroToday
|
[Immunotherapy in renal cell carcinoma: A booming clinical research].
UroToday Nivolumab, an anti-PD1 immune control point inhibitor, is the first treatment that has improved the overall survival of patients after first-line metastatic renal cell carcinoma in 2015. Over the past two years, a large number of trials on these … |
